Product Categories
| Country: | China |
|---|---|
| Tel: | |
| Mobile: | +undefined13424074264 |
| E-mail: | pengguizi@cti-cert.com |
| QQ: | |
| Skype: | Chat Now! |
| Address: | Room A701, B701, C701, No. 203, Bohua 1st Road, Huangpu District, Guangzhou |
| Product Name | MF | CAS | Details |
|---|
| LenalidoMide; PhEur/USP(DMF) | C13H13N3O3 | 191732-72-6 | Details |
| lenvatinib Mesylate; PhEur/USP(DMF) | C22H23ClN4O7S | 857890-39-2 | Details |
| 5-BROMOVERATRALDEHYDE; PhEur/USP(DMF) | C9H9BrO3 | 6948-30-7 | Details |
| tert-butyl 4-((1R,2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate; PhEur/USP(DMF) | C24H34N4O5 | 1174020-63-3 | Details |
| 1,3-Benzodioxole,5-[(1E)-2-nitroethenyl]-; PhEur/USP(DMF) | C9H7NO4 | 22568-48-5 | Details |
| Pomalidomide; PhEur/USP(DMF) | C13H11N3O4 | 19171-19-8 | Details |
| 2-(3-bromo-4,5-dimethoxyphenyl)ethan-1-amine hydrochloride; PhEur/USP(DMF) | C10H14BrNO2.ClH | 92015-18-4 | Details |
| Dasatinib; PhEur/USP(DMF) | C22H26ClN7O2S | 302962-49-8 | Details |
| (2S,3S,4R)-ethyl 4-(benzo[d][1,3]dioxol-5-yl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylate; PhEur/USP(DMF) | C21H23NO5 | 173937-93-4 | Details |
| Olaparib; PhEur/USP(DMF) | C24H23FN4O3 | 763113-22-0 | Details |
| Ruxolitinib; PhEur/USP(DMF) | C17H18N6 | 941678-49-5 | Details |
| Osimertinib; PhEur/USP(DMF) | C28H33N7O2 | 1421373-65-0 | Details |
| Dexpanthenol Impurity2 | C{6}H{11}NaO{4} | Details |
| Trametinib Impurity 14 | Details |
| Atrasentan Impurity 27 | Details |
| Quisinostat Impurity4 | Details |
| Baricitinib Impurity 6 | C12H19N3O2Si | Details |
| Baricitinib Impurity 3 | Details |
| Atrasentan Impurity 23 | Details |
| Quisinostat Impurity3 | Details |
| Trametinib Impurity 15 | C15H16N2O3S | 329941-39-1 | Details |
| Atrasentan Impurity 22 | Details |
| Trametinib Impurity 01 | Details |
| Atrasentan Impurity 25 | Details |
| Quisinostat Impurity1 | Details |
| Baricitinib Impurity 2 | Details |
| Trametinib Impurity 02 | C13H11FIN3O2 | 871700-28-6 | Details |
| Trametinib Impurity 12 | C18H15FIN3O4 | 871700-24-2 | Details |
| Trametinib Impurity 10 | Details |
| Atrasentan Impurity 21 | Details |
| Trametinib Impurity 07 | Details |
| Quisinostat Impurity6 | Details |
| Baricitinib Impurity 5 | Details |
| Dexpanthenol Impurity1 | C6H10O3 | Details |
| Atrasentan Impurity 19 | Details |
| Quisinostat Impurity2 | Details |
| Atrasentan Impurity 18 | Details |
| Trametinib Impurity 04 | Details |
| Atrasentan Impurity 20 | Details |
| Atrasentan Impurity 28 | Details |
| Atrasentan Impurity 26 | Details |
| Trametinib Impurity 08 | Details |
| Trametinib Impurity 03 | C16H16FIN4O2 | 871700-30-0 | Details |
| Dexpanthenol Impurity3 | C10H19NO5 | Details |
| Baricitinib Impurity 4 | Details |
| Trametinib Impurity 13 | C25H21FIN3O6S | 871700-32-2 | Details |
| Trametinib Impurity 17 | C26H24FN5O4 | 871700-65-1 | Details |
| Baricitinib Impurity 7 | Details |
| Trametinib Impurity 20 | C26H23FIN5O4 | 871701-23-4 | Details |
| Quisinostat Impurity8 | Details |
| Trametinib Impurity 11 | C26H23FIN5O4 | 871700-25-3 | Details |
| Quisinostat Impurity7 | Details |
| Quisinostat Impurity5 | Details |
| Baricitinib Impurity 1 | C15H15N7O2S | Details |
| Trametinib Impurity 21 | C24H21FIN5O3 | 871701-87-0 | Details |
| Trametinib Impurity 19 | C17H17FIN3O3 | 3018911-27-5 | Details |
| Atrasentan Impurity 24 | Details |
| Trametinib Impurity 06 | Details |
| Trametinib Impurity 18 | Details |
| Trametinib Impurity 16 | C26H23FIN5O5 | Details |
| ethyl 3-(benzo[d][1,3]dioxol-5-yl)-2-(4-methoxybenzoyl)-4-nitrobutanoate; PhEur/USP(DMF) | C21H21NO8 | 173864-45-4 | Details |
| 1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole; PhEur/USP(DMF) | C13H23BN2O3 | 1029716-44-6 | Details |
| Sorafenib tosylate; PhEur/USP(DMF) | C21H16ClF3N4O3.C7H8O3S | 475207-59-1 | Details |
| Tofacitinib citrate; PhEur/USP(DMF) | C16H20N6O.C6H8O7 | 540737-29-9 | Details |
| Trans-5-(Benzyloxyamino)piperidine-2-carboxylic acid; PhEur/USP(DMF) | C13H18N2O3 | 1501980-29-5 | Details |
| methyl (2R,3R,4S)-4-(benzo[d][1,3]dioxol-5-yl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylate; PhEur/USP(DMF) | C20H21NO5 | 250583-09-6 | Details |
| 3-Quinuclidinone hydrochloride; PhEur/USP(DMF) | C7H12ClNO | 1193-65-3 | Details |
| Alectinib; PhEur/USP(DMF) | C30H34N4O2 | 1256580-46-7 | Details |
| (2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate; PhEur/USP(DMF) | C17H28N4O5 | 1174020-64-4 | Details |
| Methylene blue ; PhEur/USP(DMF) | C16H20ClN3OS | 122965-43-9 | Details |
| Ceritinib (LDK378); PhEur/USP(DMF) | C28H36ClN5O3S | 1032900-25-6 | Details |
| Ethyl 4-(ethoxycarbonyl)piperidine-1-acetate | C12H21NO4 | 1838-39-7 | Details |
| Atrasentan hydrochloride; PhEur/USP(DMF) | C29H38N2O6.HCl | 195733-43-8 | Details |
| 4-chloro-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine; PhEur/USP(DMF) | C12H18ClN3OSi | 941685-26-3 | Details |
| Trazodone hydrochloride; PhEur/USP(DMF) | C19H23Cl2N5O | 25332-39-2 | Details |
| Methylene Blue trihydrate; PhEur/USP(DMF) | C16H20ClN3OS | 7220-79-3 | Details |
| 3-(2-Aminoethyl)benzoic acid methyl ester HCl; PhEur/USP(DMF) | C10H14ClNO2 | 167846-36-8 | Details |
| Aceclidine hydrochloride; PhEur/USP(DMF) | C9H16ClNO2 | 6109-70-2 | Details |
| Methylene Blue; PhEur/USP(DMF) | C16H18ClN3S | 61-73-4 | Details |
| N-(3,4-dimethoxyphenethyl)-2-(3,4-dimethoxyphenyl)acetamide; PhEur/USP(DMF) | C20H25NO5 | 139-76-4 | Details |
| Nilotinib Hydrochloride; PhEur/USP(DMF) | C28H23ClF3N7O | 923288-95-3 | Details |
| 2-(1-(ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile; PhEur/USP(DMF) | C22H31N7O3SSi | 1187594-13-3 | Details |
| 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-2-(4-methoxyphenyl)-, (2R,3R,4S)-, (αS)-α-hydroxybenzeneacetate (9CI); PhEur/USP(DMF) | C27H27NO8 | 195529-63-6 | Details |
| ETHYL 4-METHOXYBENZOYLACETATE; PhEur/USP(DMF) | C12H14O4 | 2881-83-6 | Details |
| Papaverine hydrochloride; PhEur/USP(DMF) | C20H22ClNO4 | 61-25-6 | Details |
| N,N-dibutyl-2-chloro-Acetamide; PhEur/USP(DMF) | C10H20ClNO | 2567-59-1 | Details |
| (R)-(+)-Verapamilic Acid; PhEur/USP(DMF) | C16H21NO4 | 38175-99-4 | Details |
| Imatinib mesylate; PhEur/USP(DMF) | C30H35N7O4S | 220127-57-1 | Details |
| Crizotinib; PhEur/USP(DMF) | C21H22Cl2FN5O | 877399-52-5 | Details |
| (S)-(-)-Verapamilic Acid; PhEur/USP(DMF) | C16H21NO4 | 36622-24-9 | Details |
| atrasentan; PhEur/USP(DMF) | C29H38N2O6 | 173937-91-2 | Details |
| 1-(3,4-dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride; PhEur/USP(DMF) | C20H24ClNO4 | 5884-22-0 | Details |
| Erlotinib hydrochloride; PhEur/USP(DMF) | C22H24ClN3O4 | 183319-69-9 | Details |
| 1-(3-chlorophenyl)-4-(3-chloropropyl)piperazine hydrochloride; PhEur/USP(DMF) | C13H19Cl3N2 | 52605-52-4 | Details |
| GSK1120212 (DMSO solvate); PhEur/USP(DMF) | C28H29FIN5O5S | 1187431-43-1 | Details |
| 1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one; PhEur/USP(DMF) | C6H5N3O | 6969-71-7 | Details |
| Sunitinib Malate; PhEur/USP(DMF) | C26H33FN4O7 | 341031-54-7 | Details |
| Avibactam INT 1; PhEur/USP(DMF) | C17H24N2O7 | 1416134-48-9 | Details |
| tert-butyl 4-((2S,5R)-5-(benzyloxyamino)piperidine-2-carboxamido)piperidine-1-carboxylate 4-methylbenzenesulfonate; PhEur/USP(DMF) | C23H36N4O4 | 1510832-19-5 | Details |
| 2-[1-(ethylsulfonyl)azetidin-3-ylidene]acetonitrile; PhEur/USP(DMF) | C7H10N2O2S | 1187595-85-2 | Details |
| Product Total： Product Page： | ||||
| 1 2 | ||||